0.4304

6.43% -0.0296

Pre-market: .43 -0.0004 -0.09%

AEON Biopharma Inc. (AEON)

Overview News Price History Discussions Forecast

AEON Biopharma Inc. stock is traded at $0.4304, with a volume of 203.61K. It is down -6.43% in the last 24 hours and down -35.87% over the past month. AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.

Previous Close:

$0.46

Open:

$0.4672

24h Volume:

203.61K

Relative Volume:

0.08

Market Cap:

$4.21M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+6.27%

1M Performance:

-35.87%

6M Performance:

-99.41%

1Y Performance:

-99.86%

1-Day Range:

$0.4302

$0.4672

1-Week Range:

$0.3795

$0.4797

52-Week Range:

$0.375

$402.48

AEON Biopharma Inc. Stock (AEON) Company Profile

Name

AEON Biopharma Inc.

Sector

Healthcare (1155)

Industry

Biotechnology (677)

Phone

(949) 354-6499

Address

5 Park Plaza, Suite 1750, Irvine

Employee

Twitter

Next Earnings Date

Latest SEC Filings

AEON's Discussions on Twitter

Compare AEON with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AEON AEON Biopharma Inc.	0.4304	4.21M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-18-23	Initiated	H.C. Wainwright	Buy

AEON Biopharma Inc. Stock (AEON) Latest News

Apr 25, 2025

AEON Biopharma gets NYSE American nod for compliance plan - Investing.com

Apr 25, 2025

AEON Biopharma gets NYSE American nod for compliance plan By Investing.com - Investing.com India

Apr 25, 2025

AEON Biopharma Says NYSE American Accepts Plan to Regain Compliance - marketscreener.com

Apr 25, 2025

AEON Biopharma Receives Acceptance from NYSE American to Regain Compliance with Listing Standards - Nasdaq

Apr 25, 2025

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times

Apr 25, 2025

NYSE American Grants AEON Biopharma 2-Year Lifeline to Meet Listing Requirements - Stock Titan

Apr 25, 2025

Apr 24, 2025

What was AEON Biopharma Inc (AEON)’s performance in the last session? - uspostnews.com

Apr 24, 2025

Analyzing the Impact of Earnings Reports on AEON Biopharma Inc Inc. (AEON) Price Performance - investchronicle.com

Apr 24, 2025

Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com

Apr 24, 2025

Apr 22, 2025

AEON Biopharma, Inc. Announces Executive Changes, Effective as of April 4, 2025 - marketscreener.com

Apr 22, 2025

AEON Biopharma announces CEO appointment - MSN

Apr 22, 2025

Apr 21, 2025

AEON Biopharma names Rob Bancroft as new CEO By Investing.com - Investing.com South Africa

Apr 21, 2025

Aeon Biopharma Names Robert Bancroft CEO - marketscreener.com

Apr 21, 2025

AEON Biopharma Appoints New CEO Robert Bancroft - TipRanks

Apr 21, 2025

Aeon Biopharma (AEON) Appoints Rob Bancroft as New CEO | AEON Stock News - GuruFocus

Apr 21, 2025

AEON Biopharma Appoints Rob Bancroft as CEO - MarketWatch

Apr 21, 2025

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times

Apr 21, 2025

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer - The Manila Times

Apr 21, 2025

AEON Biopharma names Rob Bancroft as new CEO - Investing.com

Apr 21, 2025

AEON Biopharma Appoints New CEO Rob Bancroft: Inside the $1M+ Executive Compensation Deal - Stock Titan

Apr 21, 2025

Former Revance Therapeutics Leader Takes AEON Helm: Inside the Race to Challenge BOTOX's $3B Market - Stock Titan

Apr 21, 2025

Apr 15, 2025

AEON Biopharma (NASDAQ:AEON) Trading 2.5% Higher – Time to Buy? - Defense World

Apr 15, 2025

Apr 08, 2025

AEON Biopharma announces new interim CEO and CFO By Investing.com - Investing.com Australia

Apr 08, 2025

AEON Biopharma Appoints Jost Fischer as Interim CEO - TipRanks

Apr 08, 2025

AEON Biopharma announces new interim CEO and CFO - Investing.com

Apr 08, 2025

Trading Day Triumph: AEON Biopharma Inc (AEON) Ends at 0.42, a -10.60 Surge/Plunge - DWinneX

Apr 08, 2025

Apr 07, 2025

Aesthetic Medicine Powerhouse: BOTOX Veteran Takes Helm at Jeune Aesthetics - Stock Titan

Apr 07, 2025

Apr 03, 2025